Omar Nadeem

15PUBLICATIONS
153CO-AUTHORS
Regenerative medicine (incl. stem cells)Haematological tumoursMedical infection agents (incl. prions)Epidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 12, 2026
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial.

|Jun 03, 2026
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

|Apr 27, 2026
Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study.

|Apr 21, 2026
eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

|Apr 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

|Apr 08, 2026
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Omar Nadeem, Michelle P Aranha, Robert A Redd

Pageof 3

Frequent Collaborators

8 joint publications

Irene M Ghobrial

7 joint publications

Adam S Sperling

5 joint publications

Shonali Midha

5 joint publications

Gad Getz